April 25, 2025
| Today’s news and insights for biopharma leaders
The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for Trodelvy and its cancer cell therapies.
|
The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid to focus resources on a pair of cancer cell therapies.
|
News roundup
Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an FDA rejection dragged on, while Sanofi revealed an immune drug setback.
|
Study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of research overnight. Explore how a new class of drugs could mark the future of immunotherapy in
|
UPDATED
Despite data pointing to a slowdown in company creation, at least four biotech startups have raised seeds or Series A rounds since the start of April, the most in a single month since January.
|
The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.
|
|
Without in-house expertise, navigating the complexities of radiopharmaceutical trials can be overwhelming. Examine the roadmap from clinical development to commercialization in this playbook.
|
|
From Our Library
Trendline
Supported by Phil Inc
|
Playbook
Custom content for Salesforce & Cognizant
|
Playbook
Custom content for Premier Research
|
Playbook
Custom content for Cardinal Health
|
| 
